Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study
June 25 2020 - 8:00AM
Diversigen, Inc., a subsidiary of OraSure Technologies Inc.
(NASDAQ:OSUR), and Alimentiv Inc. (formerly Robarts Clinical
Trials) today announced they have signed a collaboration agreement
for a research study on patients with Acute Severe Ulcerative
Colitis (ASUC).
The study, titled: “Pharmacokinetics of
Infliximab and Tumor Necrosis Factor Concentrations in Serum,
Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
(PROTOS Study),” is designed to provide new insights into the
molecular determinants of response to infliximab (IFX) in patients
with ASUC. Under the terms of the agreement, the companies will
co-fund the study. ASUC is the most aggressive presentation of
ulcerative colitis (UC), and occurs in 15 percent of adults and
children with UC. Thirty patients with ASUC who are starting
infliximab in an acute setting will be recruited for the study.
The results will be jointly owned by Diversigen
and Alimentiv, and the data will be co-published upon completion of
the study.
“This is an exciting collaboration whereby we
can apply our full gamut of precision medicine tools to better
understand the molecular factors influencing drug response, which
may provide the potential to address an unmet medical need in
patients with ASUC,” said Dr. Niels Vande Casteele, Director,
Precision Medicine, Alimentiv Inc. and Assistant Professor of
Medicine, University of California San Diego. “We believe that
Diversigen is the best partner for this precision medicine study
given their outstanding track record of studying the microbiome in
clinical trials. Our team is thrilled about the prospect of working
with such a successful partner.”
“Alimentiv is recognized for their expertise in
inflammatory bowel disease (IBD) and clinical trial design and are
at the forefront of accelerating gastro-intestinal (GI) drug
development with precision medicine,” said Joy Nassif, Vice
President, Services at Diversigen Inc. “We are proud that they are
utilizing Diversigen’s science-driven, high-quality CLIA-customized
solutions for metagenomics sequencing, bioinformatics, and
statistical analysis for the study of the microbiome and look
forward to deriving new insights that could lead to improvements in
the treatment of patients with ASUC.”
Together Diversigen and Alimentiv will deliver
end-to-end support for this precision medicine study. Alimentiv
will leverage Diversigen’s expertise in metagenomic sequencing and
analysis of the cohort samples. As overall study sponsor, Alimentiv
will provide full service clinical study management, imaging and
precision medicine services.
About Alimentiv Inc.
[formerly Robarts Clinical Trials]Alimentiv is a global
research organization providing clinical trial, central image
management and precision medicine services to the pharmaceutical
and biotechnology industries. Headquartered in London Ontario,
Canada, Alimentiv employs more than 300 people across its
operations in Canada, the United States, Europe, and Latin America.
Its unique model combines the efforts of leading, internationally
recognized academic researchers with operational experts to offer
integrated solutions to its customers. Founded in 1986 at the
Robarts Research Institute, the clinical trials division was
initially led by Dr. Henry Barnett. In 1997, Dr. Brian Feagan,
Professor of Medicine, Epidemiology & Biostatistics at Western
University assumed leadership and built upon the foundation of
academic excellence by focusing the organization on Inflammatory
Bowel Disease (IBD) research. Over the past 20 years, Alimentiv has
become recognized as an expert in clinical trial design, central
image management solutions, outcome measure development, and
precision medicine for drug development in IBD. Today, Alimentiv
provides services in over 60 countries worldwide, collaborates with
leading academic research institutions across the globe, and
partners with many of the leading pharmaceutical and biotechnology
organizations to bring new and improved treatment options to
patients with GI disease.
About Diversigen
Inc.Diversigen, Inc. is a subsidiary of OraSure
Technologies Inc. Diversigen and another OraSure subsidiary,
CoreBiome, Inc., came together to create one company under the
Diversigen brand that is powering microbiome
discovery through sequencing, analysis, and
consulting services geared toward the study of the microbiome of
living organisms and environments. Diversigen provides consultative
end-to-end solutions for sequencing, bioinformatics, and
statistical analysis for the study of the microbiome of living
organisms and environments. Diversigen, Inc. operates a
state-of-the-art CLIA accredited laboratory deploying a variety of
techniques to extract high quality nucleic acids from a multitude
of sample types for subsequent metagenomics analysis. Diversigen’s
flexible sequencing and computing capacity, combined with ongoing
improvements in analytic tools and their applications, allows for
customized project-specific strategies. For more information, visit
www.diversigen.com or contact info@diversigen.com.
About OraSure Technologies
OraSure Technologies empowers the global
community to improve health and wellness by providing access to
accurate, essential information. Together with its wholly owned
subsidiaries, DNA Genotek, Diversigen, Core Biome (now operating
under the Diversigen brand) and Novosanis, OraSure provides its
customers with end-to-end solutions that encompass tools, services
and diagnostics. The OraSure family of companies is a leader in the
development, manufacture, and distribution of rapid diagnostic
tests, sample collection and stabilization devices, and molecular
services solutions designed to discover and detect critical medical
conditions. OraSure’s portfolio of products is sold globally to
clinical laboratories, hospitals, physician’s offices, clinics,
public health and community-based organizations, research
institutions, government agencies, pharma, commercial entities and
direct to consumers. For more information on OraSure Technologies,
please visit www.orasure.com.
Investor Contact: Sam MartinArgot
Partners212-600-1902orasure@argotpartners.com |
Media Contact: Jeanne MellVP
Corporate Communications484-353-1575media@orasure.com |
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Apr 2023 to Apr 2024